清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery

医学 SABR波动模型 外科 肺癌 临床终点 阶段(地层学) 随机对照试验 解剖(医学) 倾向得分匹配 放射治疗 内科学 波动性(金融) 金融经济学 生物 古生物学 经济 随机波动
作者
Joe Yujiao Chang,Reza John Mehran,Lei Feng,Vivek Verma,Zhongxing X. Liao,James William Welsh,Steven Hsesheng Lin,Michael S. O’Reilly,Melenda D. Jeter,Peter A. Balter,Stephen E. McRae,Donald A. Berry,John Victor Heymach,Jack A. Roth,Mara B. Antonoff,Wayne Lewis Hofstetter,Ravi Rajaram,David C. Rice,Boris Sepesi,Stephen G. Swisher
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:22 (10): 1448-1457 被引量:324
标识
DOI:10.1016/s1470-2045(21)00401-0
摘要

A previous pooled analysis of the STARS and ROSEL trials showed higher survival after stereotactic ablative radiotherapy (SABR) than with surgery for operable early-stage non-small-cell lung cancer (NSCLC), but that analysis had notable limitations. This study reports long-term results of the revised STARS trial, in which the SABR group was re-accrued with a larger sample size, along with a protocol-specified propensity-matched comparison with a prospectively registered, contemporary institutional cohort of patients who underwent video-assisted thoracoscopic surgical lobectomy with mediastinal lymph node dissection (VATS L-MLND).This single-arm prospective trial was done at the University of Texas MD Anderson Cancer Center (Houston, TX, USA) and enrolled patients aged 18 years or older with a Zubrod performance status of 0-2, newly diagnosed and histologically confirmed NSCLC with N0M0 disease (squamous cell, adenocarcinoma, large cell, or NSCLC not otherwise specified), and a tumour diameter of 3 cm or less. This trial did not include patients from the previous pooled analysis. SABR dosing was 54 Gy in three fractions (for peripheral lesions) or 50 Gy in four fractions (for central tumours; simultaneous integrated boost to gross tumour totalling 60 Gy). The primary endpoint was the 3-year overall survival. For the propensity-matching analysis, we used a surgical cohort from the MD Anderson Department of Thoracic and Cardiovascular Surgery's prospectively registered, institutional review board-approved database of all patients with clinical stage I NSCLC who underwent VATS L-MLND during the period of enrolment in this trial. Non-inferiority could be claimed if the 3-year overall survival rate after SABR was lower than that after VATS L-MLND by 12% or less and the upper bound of the 95% CI of the hazard ratio (HR) was less than 1·965. Propensity matching consisted of determining a propensity score using a multivariable logistic regression model including several covariates (age, tumour size, histology, performance status, and the interaction of age and sex); based on the propensity scores, one patient in the SABR group was randomly matched with one patient in the VATS L-MLND group using a 5:1 digit greedy match algorithm. This study is registered with ClinicalTrials.gov, NCT02357992.Between Sept 1, 2015, and Jan 31, 2017, 80 patients were enrolled and included in efficacy and safety analyses. Median follow-up time was 5·1 years (IQR 3·9-5·8). Overall survival was 91% (95% CI 85-98) at 3 years and 87% (79-95) at 5 years. SABR was tolerated well, with no grade 4-5 toxicity and one (1%) case each of grade 3 dyspnoea, grade 2 pneumonitis, and grade 2 lung fibrosis. No serious adverse events were recorded. Overall survival in the propensity-matched VATS L-MLND cohort was 91% (95% CI 85-98) at 3 years and 84% (76-93) at 5 years. Non-inferiority was claimed since the 3-year overall survival after SABR was not lower than that observed in the VATS L-MLND group. There was no significant difference in overall survival between the two patient cohorts (hazard ratio 0·86 [95% CI 0·45-1·65], p=0·65) from a multivariable analysis.Long-term survival after SABR is non-inferior to VATS L-MLND for operable stage IA NSCLC. SABR remains promising for such cases but multidisciplinary management is strongly recommended.Varian Medical Systems and US National Cancer Institute (National Institutes of Health).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
安详冰夏完成签到,获得积分10
9秒前
传奇3的应助被yiyixt采纳,获得10
10秒前
13秒前
喵喵发布了新的文献求助10
17秒前
风趣馒头完成签到,获得积分10
20秒前
喵喵完成签到 ,获得积分10
27秒前
月儿完成签到 ,获得积分0
37秒前
酷炫安雁完成签到,获得积分10
42秒前
43秒前
zy997987876完成签到,获得积分10
44秒前
舒心的以莲完成签到,获得积分10
1分钟前
1分钟前
369ninja发布了新的文献求助30
1分钟前
合适的太英完成签到,获得积分10
1分钟前
muyicccccc完成签到 ,获得积分10
1分钟前
潇洒小海豚完成签到,获得积分10
1分钟前
2分钟前
谦让大米完成签到,获得积分10
2分钟前
2分钟前
无辜摇伽完成签到,获得积分10
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
3分钟前
3分钟前
3分钟前
Perse完成签到,获得积分10
3分钟前
3分钟前
Perse发布了新的文献求助20
3分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179961
求助须知:如何正确求助?哪些是违规求助? 9570183
关于积分的说明 21808480
捐赠科研通 7775832
什么是DOI,文献DOI怎么找? 3433251
关于科研通互助平台的介绍 2557373
邀请新用户注册赠送积分活动 2478958